AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22643198 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care benefits
Number of subjects: 0
Study 22643198 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care benefits plus additional supports
Number of subjects: 0
Study 22643198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20713293 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ uterine repair (n = 2462)
Number of subjects: 4925
Study 20713293 — intervention group
Group type: COMPARATOR
Intervention: Extra-abdominal uterine repair (n = 2463)
Number of subjects: 4925
Study 18612151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (paclitaxel plus carboplatin)
Number of subjects: 229
Study 15695472 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarity Therapy (PT) treatments (1 or 2 treatments)
Number of subjects: 15
Study 15695472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PT treatments)
Number of subjects: 15
Study 12406667 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate bid (800 mcg) via jet nebulizer
Number of subjects: 27
Study 12406667 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate bid (800 mcg) via ultrasonic nebulizer
Number of subjects: 27
Study 12406667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 10427579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist participation in daily ward rounds, soliciting information, and reviewing charts
Number of subjects: 1959
Study 10427579 — intervention group
Group type: COMPARATOR
Intervention: Voluntary reports from physicians and nurses
Number of subjects: 1959
Study 8908382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.6 g n‐3 fatty acids/day)
Number of subjects: 36
Study 8908382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 36
Study 2057245 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg of phospholipids/kg)
Number of subjects: 430
Study 6405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 791
Study 6405764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study 31416602 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic implants
Number of subjects: 84
Study 31416602 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable implants
Number of subjects: 84
Study 31416602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 29157723 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT)
Number of subjects: 52
Study 29157723 — intervention group
Group type: COMPARATOR
Intervention: No Defibrillation Testing (No DT)
Number of subjects: 52
Study 29157723 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 52
Study 26803913 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day, 250 mg twice daily) added to lipid-lowering therapy
Number of subjects: 860
Study 26803913 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering agents (control group)
Number of subjects: 860
Study 24328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine withdrawal syndrome in smokers with mental illness
Number of subjects: 10664
Study 24328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-related symptoms as markers of withdrawal
Number of subjects: 10664
Study 24328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking among smokers with mental illness
Number of subjects: 10664
Study 24328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence and withdrawal effects on quit attempts
Number of subjects: 10664
Study 22378733 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 (flavanols only)
Number of subjects: 12
Study 22378733 — intervention group
Group type: EXPERIMENTAL
Intervention: D1-10 (flavanols and procyanidins)
Number of subjects: 12
Study 22378733 — intervention group
Group type: COMPARATOR
Intervention: D2-10 (procyanidins only)
Number of subjects: 12
Study 20489088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential scanning mode
Number of subjects: 685
Study 20489088 — intervention group
Group type: COMPARATOR
Intervention: Helical scanning mode
Number of subjects: 685
Study 17548203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100mg) twice daily orally
Number of subjects: 60
Study 17548203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15322742 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 355
Study 15322742 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 355
Study 15322742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 15322742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined teriparatide treated groups
Number of subjects: 355
Study 11999593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in 100% oxygen
Number of subjects: 24
Study 11999593 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with 50% nitrous oxide in oxygen
Number of subjects: 24
Study 10464463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training program for osteoporotic patients (10 weeks duration)
Number of subjects: 0
Study 10464463 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg losartan once daily
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg losartan once daily
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg losartan once daily
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily after 12 weeks
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg losartan once daily after 12 weeks
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg losartan once daily after 12 weeks
Number of subjects: 154
Study 7828295 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (all doses)
Number of subjects: 154
Study 2006662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 822
Study 2006662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 7049364 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU (130 mg/m2 every 6 weeks) + dexamethasone (4‐20 mg daily)
Number of subjects: 0
Study 7049364 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU (130 mg/m2 every 6 weeks)
Number of subjects: 0
Study 7049364 — intervention group
Group type: EXPERIMENTAL
Intervention: VM‐26 (100 mg/m2) + CCNU (130 mg/m2 every 6 weeks)
Number of subjects: 0
Study 7049364 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine (3‐week courses of 150 mg/m2/day)
Number of subjects: 0
Study 7049364 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids only
Number of subjects: 0
Study 30892603 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA induction regimen (oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks)
Number of subjects: 27
Study 30892603 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA maintenance treatment (14 total exposures for 9 months)
Number of subjects: 27
Study 30892603 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (high density of histologic infiltrate and high percentage of clonal TCR sequences in skin biopsy specimens)
Number of subjects: 27
Study 30892603 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA induction and maintenance phases
Number of subjects: 27
Study 29156910 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 8-Gy RT for painful bone metastases
Number of subjects: 52
Study 25417709 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral conjugated equine estrogen (oCEE, 0.45 mg)
Number of subjects: 83
Study 25417709 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly transdermal 17β‐estradiol (tE2, 50 μg)
Number of subjects: 83
Study 25417709 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 83
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 70 mg every 2 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 105 mg every 2 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 140 mg every 2 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 280 mg every 4 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 350 mg every 4 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG145 420 mg every 4 weeks
Number of subjects: 631
Study 23884353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 21091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 10 mg once daily, with potential dose increase to 40 mg
Number of subjects: 351
Study 21091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 10 mg once daily
Number of subjects: 351
Study 21091270 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (R) 2.5 mg once daily, with potential dose increase to 10 mg
Number of subjects: 351
Study 21091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (O)
Number of subjects: 351
Study 21091270 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 351
Study 21091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (O) and Ramipril (R)
Number of subjects: 351
Study 19505206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 19505206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17482847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (n=9)
Number of subjects: 16
Study 17482847 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (n=7)
Number of subjects: 16
Study 15124990 — intervention group
Group type: EXPERIMENTAL
Intervention: AGIMRT (6.5 Gy and 1.8 Gy)
Number of subjects: 10
Study 15124990 — intervention group
Group type: EXPERIMENTAL
Intervention: AGIMRT
Number of subjects: 10
Study 15124990 — intervention group
Group type: COMPARATOR
Intervention: HDR
Number of subjects: 10
Study 11773175 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy of cranial irradiation (hyperfractionated)
Number of subjects: 369
Study 11773175 — intervention group
Group type: COMPARATOR
Intervention: 18 Gy of cranial irradiation (conventionally fractionated)
Number of subjects: 369
Study 11773175 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (standard-risk patients did not receive cranial irradiation)
Number of subjects: 369
Study 11773175 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (high-risk/very high-risk patients received cranial irradiation)
Number of subjects: 369
Study 9551595 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro; Lilly)
Number of subjects: 0
Study 9551595 — intervention group
Group type: COMPARATOR
Intervention: low-dose or standard-dose weight-adjusted heparin
Number of subjects: 0
Study 9551595 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab, eptifibatide (INTEGRILIN; Cor/Schering), tirofiban
Number of subjects: 0
Study 8123633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular irrigation fluid with 1:1,000,000 adrenaline
Number of subjects: 70
Study 8123633 — intervention group
Group type: COMPARATOR
Intervention: Control group (intraocular irrigation fluid without adrenaline)
Number of subjects: 70
Study 2561042 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-laser vaporization
Number of subjects: 119
Study 2561042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 119
Study 2561042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lesions (HPV‐CIN & HPV‐VAIN) treated by laser
Number of subjects: 119
Study 2561042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and CO2-laser vaporization
Number of subjects: 119
Study 24980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 17
Study 24980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosazepam 60 mg
Number of subjects: 17
Study 24980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 17
Study 30981954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole, administered as multiple oral doses, specific dosage not mentioned.
Number of subjects: 0
Study 30981954 — intervention group
Group type: COMPARATOR
Intervention: Albendazole, used as an internal standard in the assay.
Number of subjects: 0
Study 26231151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise group (n = 24)
Number of subjects: 50
Study 26231151 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 50
Study 25038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0
Study 25038874 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 25038874 — intervention group
Group type: COMPARATOR
Intervention: HER2-positivity analysis
Number of subjects: 0
Study 25038874 — intervention group
Group type: COMPARATOR
Intervention: HER2 testing
Number of subjects: 0
Study 23269720 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis in-plane technique
Number of subjects: 46
Study 23269720 — intervention group
Group type: COMPARATOR
Intervention: Short-axis in-plane technique
Number of subjects: 46
Study 23271905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity noninvasive ventilation (high-pressure and high backup rate)
Number of subjects: 12
Study 23271905 — intervention group
Group type: COMPARATOR
Intervention: High-pressure noninvasive ventilation (high-pressure and low backup rate)
Number of subjects: 12
Study 19389743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Qigong training
Number of subjects: 44
Study 19389743 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 44
Study 17430732 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucous myomas
Number of subjects: 0
Study 17430732 — intervention group
Group type: COMPARATOR
Intervention: Uterine myomas
Number of subjects: 0
Study 15471149 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular stimulation (cardiac resynchronization therapy)
Number of subjects: 0
Study 15471149 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11520379 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused 20-minute educational session on evaluation and feedback, accompanied by 3 by 5 reminder card and diary, given to faculty at the start of their attending month.
Number of subjects: 157
Study 11520379 — intervention group
Group type: COMPARATOR
Intervention: Control group (faculty not receiving the educational intervention).
Number of subjects: 157
Study 9749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Layer V dendritic pattern
Number of subjects: 8
Study 9749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Layer IIIc neurons
Number of subjects: 8
Study 7831649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (low molecular weight heparin) administered subcutaneously once daily at a fixed dose of 200 IU anti-factor Xa/kg
Number of subjects: 204
Study 7831649 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of unfractionated heparin (UFH)
Number of subjects: 204
Study 7831649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 204
Study 7831649 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 204
Study 2966546 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 1 mg/kg
Number of subjects: 12
Study 2966546 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 2 mg/kg
Number of subjects: 12
Study 2966546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29112086 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 100
Study 29112086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30187734 — intervention group
Group type: EXPERIMENTAL
Intervention: IBA 0.25 mg L‐1 and kinetin 1 mg L‐1
Number of subjects: 8
Study 30187734 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no added NAA and IBA)
Number of subjects: 8
Study 26290236 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain patients
Number of subjects: 51
Study 26290236 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy human subjects
Number of subjects: 51
Study 26290236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 26290236 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual responsiveness of the external‐task‐positive ventrolateral prefrontal cortex
Number of subjects: 51
Study 23139428 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 182
Study 23139428 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 182
Study 23139428 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 182
Study 21498915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study 21498915 — intervention group
Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 60
Study 18803795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (pill)
Number of subjects: 628
Study 16979701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 746
Study 16979701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 746
Study 16979701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746
Study 12684357 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program (n = 211) consisting of a food plan, activity plan, and cognitive restructuring behavior modification plan, delivered at weekly meetings.
Number of subjects: 423
Study 12684357 — intervention group
Group type: COMPARATOR
Intervention: Self-help program (n = 212) consisting of two 20-minute counseling sessions with a nutritionist and provision of self-help resources.
Number of subjects: 423
Study 12684357 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 423
Study 12684357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 423
Study 11022850 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid diet
Number of subjects: 0
Study 11022850 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid diet
Number of subjects: 0
Study 8957573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrifazid (rifampicin+isoniazid+sulfamethoxazole+trimethoprim)
Number of subjects: 61
Study 1549990 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1,500,000 units over 1 hour)
Number of subjects: 122
Study 1549990 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA (100 mg over 3 hours)
Number of subjects: 122
Study 1549990 — intervention group
Group type: COMPARATOR
Intervention: rTPA
Number of subjects: 122
Study 1549990 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 122
Study 3698694 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (encouraged by a specialized respiratory physiotherapist to breathe deeply for five minutes hourly, 12 times daily, for three postoperative days)
Number of subjects: 40
Study 3698694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specialized postoperative respiratory care)
Number of subjects: 40
Study 3698694 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 40
Study 27322812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (HT) supplementation for 8 weeks in rodents
Number of subjects: 0
Study 27322812 — intervention group
Group type: COMPARATOR
Intervention: Hydroxytyrosol (HT) supplementation in healthy volunteers
Number of subjects: 0
Study 24804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic visual signal (rotary motion direction of an annulus of random dots)
Number of subjects: 0
Study 24804788 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic auditory signal (direction of an auditory pitch glide)
Number of subjects: 0
Study 23104212 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-high status
Number of subjects: 1404
Study 23104212 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 focal loss of expression
Number of subjects: 1404
Study 23104212 — intervention group
Group type: EXPERIMENTAL
Intervention: 18qLOH
Number of subjects: 1404
Study 20921834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water (D5W) injection before catheter placement
Number of subjects: 70
Study 20921834 — intervention group
Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 70
Study 18514618 — intervention group
Group type: EXPERIMENTAL
Intervention: Special oral nutritional mixture of amino acids (AAs) 4 g twice daily (n = 43)
Number of subjects: 95
Study 18514618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 95
Study 16781338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minocycline (1.0 mg in bioresorbable polyglycolide‐co‐dl‐lactide [PGLA] sustained‐release microspheres)
Number of subjects: 63
Study 16781338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 63
Study 16781338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minocycline
Number of subjects: 63
Study 14585449 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Group 1)
Number of subjects: 120
Study 14585449 — intervention group
Group type: COMPARATOR
Intervention: Antacid + Donnatal (Group 2)
Number of subjects: 120